NCT01432535View on ClinicalTrials.gov

Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Renal Insufficiency
Interventions
DRUG

PegIFN-2b (Sylatron®)

Single 4.5 μg/kg dose

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01432535 - Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655) | Biotech Hunter | Biotech Hunter